Keywords: Gilead Sciences, Viread, European Commission, HIV, Almirall, Ironwood, Constella, IBS, Merck & Co, Vintafolide, Endocyte, Etarfolatide, Ovarian cancer
EU approvals for Viread and Constella; EMA accepts vintafolide MAA
Article | 29 November 2012
Among a batch of European Union regulatory news in the last day or two, US biotech firm Gilead Sciences (Nasdaq: ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
